26 Feb 2021

Merck signs agreement to buy Pandion Therapeutics for $1.85bn

Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates. Under the agreement, Merck will initiate a tender offer through…

19 Feb 2021

Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors

Eli Lilly and Company and Rigel Pharmaceuticals have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialise the latter’s receptor-interacting serine / threonine-protein kinase 1…